Skip to content

Main Navigation

Clinical Study

Nintedanib: A Study Drug for COVID-19 Interstitial Lung Disease (ILD)

Nintedanib is a study drug to slow the rate of lung scarring from interstitial lung disease (ILD), a lung injury caused by COVID-19. Scientists and doctors do not know the effectiveness of the treatment. Research is needed to learn if the drug may be approved and used to improve the health of people suffering from ILD.


For more information contact:

Cassie Larsen

IRB#: IRB_00148442 | PI: Sean Callahan | Department: PULMONARY | Approval Date: 2022-01-20 07:00:00
Study Categories: COVID-19 Studies | Specialties: Pulmonary

Who can participate?

 Gender: All

 Age: Over 18 years old

 Volunteers: Volunteers with special conditions

 Location: In Person

 COVID-19 Study

Inclusion Criteria:

  • All genders 18+
  • In-person at University of Utah
  • At least 30 days passed since first symptoms and positive COVID-19 test
  • After COVID-19 diagnosis, required supplemental oxygen, noninvasive ventilation such as CPAP or BIPAP, or mechanical ventilation
  • Signs of interstitial lung disease

Exclusion Criteria:

  • Active COVID-19 infection
  • Active Hepatitis A/B/C
  • Pregnant or breastfeeding women
  • Pre-existing interstitial lung disease and/or liver disease
  • Patients in an intensive care unit (ICU) or in the step-down unit if on invasive or non-invasive mechanical ventilation, ECMO, or high flow nasal cannula oxygen

Will I be paid for my time?


Last Updated: 4/5/21